MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-14-2026
GlaxoSmithKline plc Total Non Current Liabilities 2011-2026 | GSK
Annual Total Non Current Liabilities GlaxoSmithKline plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 37.5 B | -37.3 B | -31.9 B | -26.3 B | -35.1 B | -31.2 B | -22.4 B | -20.6 B | -20.9 B | -17.2 B |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.5 B | -37.3 B | -20.5 B |
Quarterly Total Non Current Liabilities GlaxoSmithKline plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 34.1 B | - | - | - | 37.5 B | - | - | - | 37.3 B | - | - | - | 31.9 B | - | - | - | 26.3 B | - | - | - | 35.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 37.5 B | 26.3 B | 33.7 B |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
108 M | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
Voyager Therapeutics
VYGR
|
179 M | $ 3.96 | -4.12 % | $ 232 M | USA |
 |
VistaGen Therapeutics
VTGN
|
4.16 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
21.2 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
17.2 M | $ 6.37 | 2.66 % | $ 1.07 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
27 K | $ 2.72 | -2.86 % | $ 4.63 M | USA |
 |
XBiotech
XBIT
|
1.12 M | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
12.3 M | $ 54.48 | -1.89 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
97.2 M | $ 5.4 | -3.05 % | $ 866 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
22 M | $ 4.04 | -6.26 % | $ 171 M | USA |
 |
Xencor
XNCR
|
10.5 M | $ 11.42 | -7.23 % | $ 848 M | USA |
 |
XOMA Corporation
XOMA
|
26.6 M | $ 30.17 | -1.18 % | $ 364 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
22nd Century Group
XXII
|
241 K | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | USA |
 |
Zai Lab Limited
ZLAB
|
13.9 M | $ 18.0 | 2.8 % | $ 19.7 B | China |
|
Enlivex Therapeutics Ltd.
ENLV
|
299 K | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
425 K | - | - | $ 40.5 M | USA |